Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 14;14(1):176.
doi: 10.1038/s41408-024-01159-8.

Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma

Annika Werly #  1 , Mareike Hampel #  1 , Thomas Hielscher  2 , Kosima Zuern  1 , Sophia K Schmidt  1 , Alissa Visram  3 , Marc S Raab  1 , Carsten Mueller-Tidow  1 , Hartmut Goldschmidt  1   4 , Elias K Mai  5
Affiliations

Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma

Annika Werly et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

EKM reports consulting or advisory role with Amgen, BMS/Celgene, GlaxoSmithKline, Janssen-Cilag, Pfizer, Sanofi, Stemline, and Takeda; honoraria from Amgen, BMS/Celgene, GlaxoSmithKline, Janssen-Cilag, Pfizer, Sanofi, Stemline, and Takeda; research funding from BMS/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi, and Takeda; and travel accommodations and expenses from BMS/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi, Stemline, and Takeda. AV reports consulting and honoraria fees from Sanofi, Pfizer, Janssen, and Forus, and research funding from Janssen. All other authors declare no competing interests.

Figures

Fig. 1
Fig. 1. MDEs in patients with smoldering multiple myeloma according to high, low/intermediate or unknown risk status.
MDE myeloma defining event, MM multiple myeloma, BMPCs bone marrow plasma cells, FLCr free light chain ratio, MRI magnetic resonance imaging, FL focal lesion.
Fig. 2
Fig. 2. Distribution of MDE among patients with smoldering multiple myeloma according to SLiM-CRAB criteria.
MDE myeloma defining event, S: ≥60% bone marrow plasma cells (BMPCs); Li: free light chain ration ≥100; M: >1 MRI-defined focal lesion, C hypercalcemia, R renal insufficiency, A anemia; B bone lesions.
See this image and copyright information in PMC

References

    1. Vaxman I, Gertz MA. How I approach smoldering multiple myeloma. Blood. 2022;140:828–38. - PMC - PubMed
    1. Bustoros M, Sklavenitis-Pistofidis R, Park J, Redd R, Zhitomirsky B, Dunford AJ, et al. Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression. J Clin Oncol. 2020;38:2380–9. - PMC - PubMed
    1. Rajkumar SV, Kumar S, Lonial S, Mateos MV. Smoldering multiple myeloma current treatment algorithms. Blood Cancer J. 2022;12:129. - PMC - PubMed
    1. Mateos M-V, Kumar S, Dimopoulos MA, González-Calle V, Kastritis E, Hajek R, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10:102. - PMC - PubMed
    1. Cowan A, Ferrari F, Freeman SS, Redd R, El-Khoury H, Perry J, et al. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. Lancet Haematol. 2023;10:e203–e212. - PMC - PubMed

Publication types

LinkOut - more resources